Advertisement
Original research| Volume 14, ISSUE 6, P672-677, December 2020

Download started.

Ok

The external validity and performance of the no-laboratory American Diabetes Association screening tool for identifying undiagnosed type 2 diabetes among the Iranian population

  • Samaneh Asgari
    Affiliations
    Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Search for articles by this author
  • Mojtaba Lotfaliany
    Affiliations
    Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Search for articles by this author
  • Noushin Fahimfar
    Affiliations
    Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
    Search for articles by this author
  • Farzad Hadaegh
    Affiliations
    Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Search for articles by this author
  • Fereidoun Azizi
    Affiliations
    Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Search for articles by this author
  • Davood Khalili
    Correspondence
    Corresponding author at: Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
    Affiliations
    Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Search for articles by this author

      Highlights

      • The ADA risk score is valid for screening undiagnosed T2DM in the Iranian population.
      • The ADA cut off 5 has a good power to classify the low and high-risk individuals.
      • The cut off 4 could also be recommended by policymakers and professionals.

      Abstract

      Aims

      The aim of this study is to assess the American Diabetes Association (ADA) risk score as a self-assessment screening tool for undiagnosed type 2 diabetes (T2DM) in Iran.

      Methods

      In a national survey of risk factors for non-communicable diseases, we included 3458 Iranian adults. The discrimination and validity were assessed using the area under the curve (AUC), sensitivity, specificity, Youden's index, positive and negative predictive values (PPV and NPV). The frequency of high-risk Iranian population who need a glucose test and those who need intervention were also estimated.

      Results

      The AUC was 73.7% and the suggested ADA score of ≥5 yielded a sensitivity of 51.6%, specificity 82.4%, NPV 98.3%, and PPV 7.9%. This threshold results in classifying 18.6% of the Iranians, equals to 8.5 million, as high-risk and 1.5% of the population, about 700,000, would need intervention. However, our study suggested score ≥4 that identified 34% of the population as high-risk and 2% of the population would need intervention.

      Conclusion

      Our findings support the ADA suggested threshold for identifying high-risk individuals for undiagnosed T2DM; however, a lower threshold is also recommended for higher sensitivity. The ADA screening tool could help the public health system for low-cost screening.

      Abbreviations:

      T2DM (Type 2 diabetes), MENA (the Middle East and North Africa region), FPG (fasting plasma glucose), 2h-PCPG (2-h post-challenge plasma glucose), HbA1c (hemoglobin A1c), ADA (American Diabetes Association), PPV and NPV (positive and negative predictive values), SuRFNCD (non-communicable Diseases), BMI (body mass index), SBP (systolic blood pressure), DBP (diastolic blood pressure), IraPEN (Package of Essential NCD interventions), CV (coefficients of variation), GPAQ (global physical activity questionnaire), LR (likelihood ratio), TC (total cholesterol), LDL-C (low-density lipoprotein-cholesterol), TG (triglyceride), AUC (area under the receiver-operating characteristic curve)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Primary Care Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ginter E.
        • Simko V.
        Type 2 diabetes mellitus, pandemic in 21st century.
        Diabetes. Springer, 2013: 42-50
        • Zimmet P.Z.
        • et al.
        Diabetes: a 21st century challenge.
        Lancet Diabetes Endocrinol. 2014; 2: 56-64
        • Ogurtsova K.
        • et al.
        IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040.
        Diabetes Res. Clin. Pract. 2017; 128: 40-50
        • Song S.
        • Hardisty C.
        Early onset type 2 diabetes mellitus: a harbinger for complications in later years-clinical observation from a secondary care cohort.
        QJM: Int. J. Med. 2009; 102: 799-806
        • Barengo N.C.
        • et al.
        A Colombian diabetes risk score for detecting undiagnosed diabetes and impaired glucose regulation.
        Primary Care Diabetes. 2017; 11: 86-93
        • Alberti K.G.M.M.
        • Zimmet P.
        • Shaw J.
        International Diabetes Federation: a consensus on Type 2 diabetes prevention.
        Diabetic Med. 2007; 24: 451-463
        • Paulweber B.
        • et al.
        A European evidence-based guideline for the prevention of type 2 diabetes.
        Hormone and Metabolic Research = Hormon-und Stoffwechselforschung = Hormones et metabolisme. 2010; 42: S3-S36
        • Health D.o.
        Putting Prevention First–NHS Health Check: Vascular Risk Assessment and Management Best Practice Guidance.
        Department of Health London, 2009
        • Collins G.S.
        • et al.
        Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting.
        BMC Med. 2011; 9: 103
        • Barber S.R.
        • et al.
        Risk assessment tools for detecting those with pre-diabetes: a systematic review.
        Diabetes Res. Clin. Pract. 2014; 105: 1-13
        • Noble D.
        • et al.
        Risk models and scores for type 2 diabetes: systematic review.
        BMJ. 2011; 343: d7163
        • Wareham N.
        • Griffin S.
        Risk scores for predicting type 2 diabetes: comparing axes and spades.
        Diabetologia. 2011; 54: 994-995
        • Association A.D.
        2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018.
        Diabetes Care. 2018; 41: S13-S27
        • Bang H.
        • et al.
        A patient self-assessment diabetes screening score: development, validation, and comparison to other diabetes risk assessment scores.
        Ann. Intern. Med. 2009; 151: 775
      1. H. Zhang, et al. A risk-score model for predicting risk of type 2 diabetes mellitus in a rural Chinese adult population: a cohort study with a 6-year follow-up. Diabetes/Metabol. Res. Rev.

        • Bernabe-Ortiz A.
        • et al.
        Development and validation of a simple risk score for undiagnosed Type 2 diabetes in a resource-constrained setting.
        J. Diabetes Res. 2016; : 2016
        • Organization W.H.
        WHO STEPS Surveillance Manual: The WHO STEPwise Approach to Chronic Disease Risk Factor Surveillance.
        World Health Organization, Geneva2005
        • Esteghamati A.
        • et al.
        Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011.
        Diabetes Res. Clin. Pract. 2014; 103: 319-327
      2. A. Takian, M. Amerzadeh, An International Comparative Policy Analysis to Accelerate Actions against Non-Communicable Diseases: The Experience of Iran.

      3. WHO, Islamic Republic of Iran on a fast-track to beating noncommunicable diseases. https://www.who.int/news-room/feature-stories/detail/islamic-republic-of-iran-on-a-fast-track-to-beating-noncommunicable-diseases.

        • Organization W.H.
        Global Physical Activity Questionnaire (GPAQ) Analysis Guide.
        2012
        • CARE I.
        Standards of Medical Care in Diabetes – 2018 Abridged for Primary Care Providers.
        2018
        • Hosmer Jr., D.W.
        • Lemeshow S.
        • Sturdivant R.X.
        Applied Logistic Regression. vol. 398. John Wiley & Sons, 2013
        • Deeks J.J.
        • Altman D.G.
        Diagnostic tests 4: likelihood ratios.
        BMJ. 2004; 329: 168-169
        • Schisterman E.F.
        • et al.
        Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples.
        Epidemiology. 2005; : 73-81
      4. Analysis of non-communicable diseases risk factors surveillance, 2016. https://vizit.report/panel/steps/fa/main.html#/errorBarSex (accessed 11.06.19).

        • Royston P.
        Multiple Imputation by the MICE System of Chained Equations.
        MRC Clinical Trials Unit, London2004: 35
        • Bang H.
        • et al.
        SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease.
        Arch. Intern. Med. 2007; 167: 374-381
        • González Tabares R.
        • Acosta González F.A.
        Utility of a risk scale to identify patients with dysglycemia.
        Rev. Cub. Med. Mil. 2017; 46: 135-147
        • Galaviz K.I.
        • et al.
        Predicting diabetes risk among HIV-positive and HIV-negative women.
        AIDS. 2018; 32: 2767-2775
        • Muchira J.M.
        • Stuart-Shor E.M.
        Using noninvasive tools to screen for prediabetes and undiagnosed diabetes: value added to cardiovascular disease prevention.
        J. Cardiovasc. Nurs. 2016; 31: 488-491
        • Perkins Neil J.
        • Schisterman Enrique F.
        The inconsistency of “optimal” cut-points using two ROC based criteria.
        Am. J. Epidemiol. 2006; 163: 670-675
        • Li C.
        • et al.
        Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity?.
        Cardiovasc. Diabetol. 2008; 7: 4
        • Khunti K.
        • et al.
        A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: modelling study.
        Diabetes Res. Clin. Pract. 2012; 97: 505-513